Can we select NSCLC patients for immune checkpoint therapy?

15 / 38

Tumor mutational burden
Yarchoan – NEJM 2017
Correlation between TMB and RR (p<0.001)
RR= 10.8 x log (X)-0.7
X= number of mutations/Mb
NSCLC, high TMB correlated with outcome
Rizvi – Science 2015
PFS: 14.5 vs. 3.7 , p=0.01